Cephalon, Inc. and Cima Labs Inc. announced that they received a request for additional information from the Federal Trade Commission (FTC) pertaining to Cephalon's pending merger with Cima.

The formal request for additional, specific information supplements information already provided in the original Hart-Scott-Rodino filing and in subsequent discussions with the FTC during the past several weeks.

This request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) during which the FTC is permitted to review a proposed transaction. The companies expect to close this transaction upon completion of the HSR clearance process, and the satisfaction of all other closing conditions contained in the merger agreement.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer and pain. Cima develops and manufactures prescription and over-the-counter products based upon its proprietary, orally disintegrating drug delivery technologies.